- Home
- PMVP vs ONCY Comparison
PMVP vs ONCY Comparison
Compare PMVP & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ONCY
- Stock Information
- Founded
- PMVP 2013
- ONCY 1998
- Country
- PMVP United States
- ONCY Canada
- Employees
- PMVP N/A
- ONCY N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ONCY Pharmaceuticals and Biotechnology
- Sector
- PMVP Health Care
- ONCY Health Care
- Exchange
- PMVP Nasdaq
- ONCY Nasdaq
- Market Cap
- PMVP 85.5M
- ONCY 103.8M
- IPO Year
- PMVP 2020
- ONCY 1999
- Fundamental
- Price
- PMVP $1.65
- ONCY $1.19
- Analyst Decision
- PMVP Strong Buy
- ONCY Strong Buy
- Analyst Count
- PMVP 4
- ONCY 2
- Target Price
- PMVP $5.75
- ONCY $4.00
- AVG Volume (30 Days)
- PMVP 185.0K
- ONCY 903.7K
- Earning Date
- PMVP 11-07-2024
- ONCY 11-05-2024
- Dividend Yield
- PMVP N/A
- ONCY N/A
- EPS Growth
- PMVP N/A
- ONCY N/A
- EPS
- PMVP N/A
- ONCY N/A
- Revenue
- PMVP N/A
- ONCY N/A
- Revenue This Year
- PMVP N/A
- ONCY N/A
- Revenue Next Year
- PMVP N/A
- ONCY N/A
- P/E Ratio
- PMVP N/A
- ONCY N/A
- Revenue Growth
- PMVP N/A
- ONCY N/A
- 52 Week Low
- PMVP $1.33
- ONCY $0.84
- 52 Week High
- PMVP $3.47
- ONCY $1.80
- Technical
- Relative Strength Index (RSI)
- PMVP 60.86
- ONCY 52.51
- Support Level
- PMVP $1.63
- ONCY $1.17
- Resistance Level
- PMVP $1.69
- ONCY $1.28
- Average True Range (ATR)
- PMVP 0.07
- ONCY 0.09
- MACD
- PMVP 0.01
- ONCY -0.01
- Stochastic Oscillator
- PMVP 52.65
- ONCY 28.00
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.